[1]Writing Group for the CKD Prognosis Consortium; Grams ME, Coresh J, Matsushita K, Ballew SH, Sang Y, Surapaneni A, Alencar de Pinho N, Anderson A, Appel LJ, ?rnl?v J, Azizi F, Bansal N, Bell S, Bilo HJG, Brunskill NJ, Carrero JJ, Chadban S, Chalmers J, Chen J, Ciemins E, Cirillo M, Ebert N, Evans M, Ferreiro A, Fu EL, Fukagawa M, Green JA, Gutierrez OM, Herrington WG, Hwang SJ, Inker LA, Iseki K, Jafar T, Jassal SK, Jha V, Kadota A, Katz R, K?ttgen A, Konta T, Kronenberg F, Lee BJ, Lees J, Levin A, Looker HC, Major R, Melzer Cohen C, Mieno M, Miyazaki M, Moranne O, Muraki I, Naimark D, Nitsch D, Oh W, Pena M, Purnell TS, Sabanayagam C, Satoh M, Sawhney S, Schaeffner E, Sch?ttker B, Shen JI, Shlipak MG, Sinha S, Stengel B, Sumida K, Tonelli M, Valdivielso JM, van Zuilen AD, Visseren FLJ, Wang AY, Wen CP, Wheeler DC, Yatsuya H, Yamagata K, Yang JW, Young A, Zhang H, Zhang L, Levey AS, Gansevoort RT. .Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. [J]. JAMA, 2023, 330(13):1266-1277
[2]Jung HH.Albuminuria, estimated glomerular filtration rate, and traditional predictors for composite cardiovascular and kidney outcome: a population-based cohort study in Korea. [J].Kidney Res Clin Pract, 2022, 41(5):567-579
[3]Mohan M, Dihoum A, Mordi IR, Choy AM, Rena G, Lang CC.Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention[J].Front Cardiovasc Med, 2021 , 8(0):746382-746382
[4]Docshin PM, Karpov AA, Mametov MV, Ivkin DY, Kostareva AA, Malashicheva AB.Mechanisms of Regenerative Potential Activation in Cardiac Mesenchymal Cells[J].Biomedicines, 2022, 10(6):1283-1283
[5]Carmona A, Guerrero F, Jimenez MJ, Ariza F, Agüera ML, Obrero T, Noci V, Mu?oz-Casta?eda JR, Rodríguez M, Soriano S, Moreno JA, Martin-Malo A, Aljama P. .Inflammation, Senescence and MicroRNAs in Chronic Kidney Disease[J]. Front Cell Dev Biol, 2020, 8(8):739-739
[6]Luttropp K, Debowska M, Lukaszuk T, Bobrowski L, Carrero JJ, Qureshi AR, Stenvinkel P, Lindholm B, Waniewski J, Nordfors L.Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease[J].Nephrol Dial Transplant, 2016, 31(12):2033-2040
[7]Amdur RL, Feldman HI, Dominic EA, Anderson AH, Beddhu S, Rahman M, Wolf M, Reilly M, Ojo A, Townsend RR, Go AS, He J, Xie D, Thompson S, Budoff M, Kasner S, Kimmel PL, Kusek JW, Raj DS; CRIC Study Investigators..Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study. [J].Am J Kidney Dis, 2019, 73(3):344-353
[8]Jankowski J, Floege J, Fliser D, B?hm M, Marx N.Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options[J]. Circulation, 2021, 143(11):1157-1172
[9]Hsu YH, Zheng CM, Chou CL, Chen YJ, Lee YH, Lin YF, Chiu HW.Therapeutic Effect of Endothelin-Converting Enzyme Inhibitor on Chronic Kidney Disease through the Inhibition of Endoplasmic Reticulum Stress and the NLRP3 Inflammasome[J].Biomedicines, 2021, 9(4):398-398
[10]Zheng T, Tan Y, Qiu J, Xie Z, Hu X, Zhang J, Na N.Alternative polyadenylation trans-factor FIP1 exacerbates UUO/IRI-induced kidney injury and contributes to AKI-CKD transition via ROS-NLRP3 axis[J].Cell Death Dis, 2021 , 12(6):512-512
[11]Schunk SJ, Kleber ME, M?rz W, Pang S, Zewinger S, Triem S, Ege P, Reichert MC, Krawczyk M, Weber SN, Jaumann I, Schmit D, Sarakpi T, Wagenpfeil S, Kramann R, Boerwinkle E, Ballantyne CM, Grove ML, Tragante V, Pilbrow AP, Richards AM, Cameron VA, Doughty RN, Dubé MP, Tardif JC, Feroz-Zada Y, Sun M, Liu C, Ko YA, Quyyumi AA, Hartiala JA, Tang WHW, Hazen SL, Allayee H, McDonough CW, Gong Y, Cooper-DeHoff RM, Johnson JA, Scholz M, Teren A, Burkhardt R, Martinsson A, Smith JG, Wallentin L, James SK, Eriksson N, White H, Held C, Waterworth D, Trompet S, Jukema JW, Ford I, Stott DJ, Sattar N, Cresci S, Spertus JA, Campbell H, Tierling S, Walter J, Ampofo E, Niemeyer BA, Lipp P, Schunkert H, B?hm M, Koenig W, Fliser D, Laufs U, Speer T; eQTLGen consortium; BIOS consortium.Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality[J].Eur Heart J, 2021, 42(18):1742-1756
[12]Suetomi T, Willeford A, Brand CS, Cho Y, Ross RS, Miyamoto S, Brown JH.Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+/Calmodulin-Dependent Protein Kinase II δ Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling[J].Circulation, 2018, 138(22):2530-2544
[13]Chen A, Lan Z, Li L, Xie L, Liu X, Yang X, Wang S, Liang Q, Dong Q, Feng L, Li Y, Ye Y, Fu M, Lu L, Yan J.Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome[J].Cardiovasc Res, 2023, 119(13):2368-2381
[14]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease[J].Kidney Int, 2024, 105(4S):S117-S314
[15]全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志, 2006, 22(10):589-595
[16]No authors listed.Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of, Cardiovascular Imaging[J].Eur Heart J Cardiovasc Imaging, 2016, 17(4):412-412
[17]顾玉, 刘秋霞, 张树良, 王媛媛, 王晓成.趋化素和胱抑素C与原发性高血压左心室肥厚的相关性[J].中华保健医学杂志, 2024, 26(2):162-164
[18]Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, Agarwal R, Mark PB, Kotanko P, Ferro CJ, Wanner C, Burnier M, Vanholder R, Wiecek A.Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association[J].Cardiovasc Res, 2023, 119(11):2017-2032
[19]Hyeon J, Kim S, Ye BM, Kim SR, Lee DW, Lee SB, Kim IY.Association of 1, 25 dihydroxyvitamin D with left ventricular hypertrophy and left ventricular diastolic dysfunction in patients with chronic kidney disease[J].PLoS One, 2024, 19(5):e0302849-e0302849
[20]Li X, Ke J, Chen X, Yin M, Lou T, Zhang J, Peng H, Wang C.Different effects of morning and nocturnal hypertension on target organ damage in chronic kidney disease[J].J Clin Hypertens (Greenwich), 2021, 23(5):1051-1059
[21]Ogawa T, Nitta K.Clinical Impact of Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease[J].Contrib Nephrol, 2018, 195(0):81-91
[22]Komada T, Muruve DA.The role of inflammasomes in kidney disease[J].Nat Rev Nephrol, 2019 , 15(8):501-520
[23]Lin YF, Lee YH, Hsu YH, Chen YJ, Lin YF, Cheng FY, Chiu HW.Resveratrol-loaded nanoparticles conjugated with kidney injury molecule-1 as a drug delivery system for potential use in chronic kidney disease[J].Nanomedicine (Lond), 2017, 12(22):2741-2756
[24] Higashikuni Y, Liu W, Numata G, Tanaka K, Fukuda D, Tanaka Y, Hirata Y, Imamura T, Takimoto E, Komuro I, Sata M.NLRP3 Inflammasome Activation Through Heart-Brain Interaction Initiates Cardiac Inflammation and Hypertrophy During Pressure Overload[J].Circulation, 2023, 147(4):338-355
[25]Suetomi T, Willeford A, Brand CS, Cho Y, Ross RS, Miyamoto S, Brown JH.Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+/Calmodulin-Dependent Protein Kinase II δ Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling[J].Circulation, 2018, 138(22):2530-2544
[26] Chen Y, Zeng M, Zhang Y, Guo H, Ding W, Sun T.Nlrp3 Deficiency Alleviates Angiotensin II-Induced Cardiomyopathy by Inhibiting Mitochondrial Dysfunction[J].Oxid Med Cell Longev, 2021, 2021(0):6679100-6679100
[27]Zhu X, Zhang X, Cong X, Zhu L, Ning Z.Inhibition of FABP4 attenuates cardiac fibrosis through inhibition of NLRP3 inflammasome activation[J].Iran J Basic Med Sci, 2022, 25(10):1260-1266
[28]He W, Wei J, Liu X, Zhang Z, Huang R, Jiang Z.Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome[J].Sci Rep, 2024, 14(1):11824-11824
[29]Zhang X, Li Y, Yang P, Liu X, Lu L, Chen Y, Zhong X, Li Z, Liu H, Ou C, Yan J, Chen M.Trimethylamine-N-Oxide Promotes Vascular Calcification Through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-κB (Nuclear Factor κB) Signals[J].Arterioscler Thromb Vasc Biol, 2020r, 40(3):751-765
